SEC Comment Letter for Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685) (VTGN) — Mar 22, 2021
Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685)
Date: March 22, 2021 · CIK: 0001411685 · Accession: 0000000000-21-003429
AI Filing Summary & Sentiment
File numbers found in text: 333-254299
Letter
United States securities and exchange commission logo March 22, 2021 Shawn K. Singh, J.D. Chief Executive Officer VistaGen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080 Re:VistaGen Therapeutics, Inc. Registration Statement on Form S-3 Filed March 15, 2021 File No. 333-254299 Dear Mr. Singh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jessica R. Sudweeks, Esq.
Show Raw Text
United States securities and exchange commission logo
March 22, 2021
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080
Re:VistaGen Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 15, 2021
File No. 333-254299
Dear Mr. Singh:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jeffrey Gabor at 202-551-2544 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jessica R. Sudweeks, Esq.